Rifamycin treatment of tuberculosis in a patient receiving atenolol: Less interaction with rifabutin than with rifampin [2]

Clinical Infectious Diseases

Volumn 37, Issue 4, 2003, Pages 607-608

  Goldberg, Stefan V ^a   Hanson, Daniel ^b   Peloquin, Charles A ^c  

^a PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN;

AGED; ANGINA PECTORIS; CASE REPORT; CLINICAL FEATURE; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; TUBERCULOSIS;

EID: 0042943224     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376648     Document Type: Letter

References (3)

1. Tattevin P, Revest M, Dupont M, Arvieux C, Michelet C. A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin. Clin Infect Dis 2003; 36:127-8.
2. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28:419-30.
3. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.